Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 4Advanced Solid Tumors 3Neoplasms 2Advanced Lung Cancer 2Tislelizumab 1Stomach Neoplasms 1Solid Tumor 1SCLC 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1High-Risk Resectable NSCLC 1Colorectal Neoplasms 1Advanced/Metastatic Solid Malignancies 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumor 1Advanced Non-Small Cell Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 3envafolimab 3Nivolumab 2trifluridine tipiracil drug combination 1tebentafusp 1surufatinib 1sintilimab 1linifanib 1Injections 1Drug Therapy 1Doxorubicin 1Combined Modality Therapy 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced or Metastatic Solid Tumors × sintilimab × Clear all
NCT04427774 2021-07-20

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
8 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡